Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration

Journal of Drug Targeting

Volumn 19, Issue 1, 2011, Pages 14-24

  Riviere, Kareen ^a   Huang, Zhaohua ^a   Jerger, Katherine ^a   MacAraeg, Nichole ^a   Szoka Jr , Francis C ^a  

^a San Francisco   (United States)

Author keywords

Drug delivery; folate receptor; KB tumor; ligand targeting

Indexed keywords

DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; ETHANOLAMINE DERIVATIVE; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MACROGOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CIRCULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; LOG RANK TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; INJECTIONS, INTRAVENOUS; KB CELLS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649939711     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003733953     Document Type: Article

References (25)

1. Abra RM, Schreier H, Szoka FC. (1982). The use of a new radioactive- iodine labeled lipid marker to follow in vivo disposition of liposomes: Comparison with an encapsulated aqueous space marker. Res Commun Chem Pathol Pharmacol, 37, 199-213.
2. Allen TM. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2, 750-763.
3. Allen TM, Cullis PR. (2004). Drug delivery systems: Entering the mainstream. Science, 303, 1818-1822.
4. Antony AC. (1992). The biological chemistry of folate receptors. Blood, 79, 2807-2820.
5. Gabizon A, Horowitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, Qazen MM, Zalipsky S. (1999). Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies. Bioconjug Chem, 10, 289-298.
6. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. (2003). In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res, 9, 6551-6559.
7. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid- anchored folic acid-PEG conjugates. Adv Drug Deliv Rev, 56, 1177-1192.
8. Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H & Zalipsky S. (2009) Improved therapeutic activity of folate- targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol.
9. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. (2000). Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res, 6, 1949-1957.
10. Hilgenbrink AR, Low PS. (2005). Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci, 94, 2135-2146.
11. Kale AA, Torchilin VP. (2007). Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target, 15, 538-545.
12. Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I. (2008). Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res, 68, 9839-9844.
13. Lee RJ, Low PS. (1994). Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem, 269, 3198-3204.
14. Lee RJ, Low PS. (1995). Folate-mediated tumor cell targeting of liposome- entrapped doxorubicin in vitro. Biochim Biophys Acta, 1233, 134-144.
15. Lu Y, Low PS. (2002). Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev, 54, 675-693.
16. Lu Y, Wu J, Gonit M, Yang X, Lee A, Xiang G, Li H, Liu S, Marcucci G, Ratnam M, Lee RJ. (2007). Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm, 4, 707-712.
17. Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41, 189-207.
18. O'Neill ID. (2009). Continued misrepresentation of KB cells as being of oral cancer phenotype requires action. Oral Oncology, 45, e117-e118.
19. Pan XQ, Wang H, Lee RJ. (2003). Antitumor activity of folate receptor- targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res, 20, 417-422.
20. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. (2002). Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 100, 594-602.
21. Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP. (2002). Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther, 9, 1542-1550.
22. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. (2006). Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up- regulated folate receptors. Mol Cancer Ther, 5, 818-824.
23. Stephenson SM, Low PS, Lee RJ. (2004). Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol, 387, 33-50.
24. Yamada A, Taniguchi Y, Kawano K, Honda T, Hattori Y, Maitani Y. (2008). Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res, 14, 8161-8168.
25. Zhao XB, Muthusamy N, Byrd JC, Lee RJ. (2007). Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate- receptor-targeted liposomes. J Pharm Sci, 96, 2424-2435.